Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Sponsor: Sun Pharma Japan Limited
Summary
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
Official title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2026-06
Completion Date
2028-09
Last Updated
2026-06-01
Healthy Volunteers
No
Conditions
Interventions
Deuruxolitinib
Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
Placebo
Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks